Doma Perpetual Capital Management LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed September 10, 2024), Doma Perpetual Capital Management LLC reported 9 stock positions worth $215.6 million. Its top holding was Davita (DVA) at 32.4% of the portfolio, followed by Inmode (INMD, 17.0%) and Pacira Biosciences (PCRX, 13.3%). Compared with Q1 2024, it opened 1 new position, sold out of 1, added to 5 and reduced 1. The biggest buy was Inmode (INMD, shares +211%) and the biggest sale Davita (DVA, shares −0%).
- Most Recent 13F
- Q2 2026
- Location
- Miami, FL
- CIK
- 0001962221
- Portfolio Value
- $215.6M (Q2 2024)
- SEC Filing
- 0001172661-24-004076 ↗ filed Sep 10, 2024
Holdings Value
Holdings 9 stocks · $215.6M
| DVA Davita Inc. | 32.36% | 503,628 | $69.8M | Reduce -0.4% |
| INMD Inmode Ltd. | 17.01% | 2,011,240 | $36.7M | Add +210.7% |
| PCRX Pacira Biosciences Inc. | 13.28% | 1,000,761 | $28.6M | Add +71.8% |
| BBD Banco Bradesco-ADR | 11.64% | 11,203,738 | $25.1M | Add +403.4% |
| LSXMK Liberty Media Corp.-Liber-New | 10.56% | 1,028,040 | $22.8M | Add +69.9% |
| HIFS Hingham Institution for SVGS | 7.10% | 85,568 | $15.3M | Add +120.9% |
| NSSC Napco Security Technologies | 4.81% | 199,514 | $10.4M | No change |
| AFYA Afya Ltd. Class A | 2.41% | 294,909 | $5.2M | No change |
| LSXMA Liberty Media Corp. Class A New | 0.82% | 80,000 | $1.8M | New |
Portfolio Sells Q1 2024 → Q2 2024
Portfolio Buys Q1 2024 → Q2 2024
| INMD Inmode Ltd. | Add +210.7% | 17.01% | +7.71 |
| BBD Banco Bradesco-ADR | Add +403.4% | 11.64% | +7.40 |
| HIFS Hingham Institution for SVGS | Add +120.9% | 7.10% | +2.60 |
| PCRX Pacira Biosciences Inc. | Add +71.8% | 13.28% | +1.96 |
| LSXMA Liberty Media Corp. Class A New | New | 0.82% | +0.82 |
| LSXMK Liberty Media Corp.-Liber-New | Add +69.9% | 10.56% | −1.39 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $430.8M | PCRX, NOMD, MBIN, INMD, HIFS |
| Q1 2026 | 11 | $372.4M | PCRX, DVA, MBIN, INMD, AFYA |
| Q4 2025 | 12 | $355.6M | PCRX, INMD, MBIN, NOMD, DVA |
| Q3 2025 | 12 | $297.8M | PCRX, NSSC, DVA, INMD, SIRI |
| Q2 2025 | 10 | $264.0M | BBD, PCRX, DVA, NSSC, INMD |
| Q1 2025 | 10 | $254.4M | PCRX, DVA, INMD, BBD, NSSC |
| Q4 2024 | 8 | $201.0M | INMD, PCRX, SIRI, BBD, NSSC |
| Q3 2024 | 8 | $198.0M | INMD, BBD, NSSC, SIRI, PCRX |
| Q2 2024Amended | 9 | $215.6M | DVA, INMD, PCRX, BBD, LSXMK |
| Q1 2024Amended | 9 | $150.3M | DVA, LSXMK, PCRX, INMD, NSSC |